Strongbridge Biopharma plc Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 06, 2020 07:30 ET
|
Strongbridge Biopharma plc
~ Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) Reaches 41 of 42 Targeted Study Participants Completing the Randomized Withdrawal Phase; One Additional Patient Currently in the Randomized...
Strongbridge Biopharma plc to Host First Quarter 2020 Financial Results Conference Call on May 6, 2020
April 20, 2020 07:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., April 20, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Present at the Cowen and Company 40th Annual Healthcare Conference
February 27, 2020 07:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
February 25, 2020 07:30 ET
|
Strongbridge Biopharma plc
~ KEVEYIS® (dichlorphenamide) Full-Year 2019 Revenue of $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million ~ ~ Full-Year 2020 KEVEYIS®(dichlorphenamide) Revenue Guidance of...
Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call on February 25, 2020
February 19, 2020 07:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces New Employment Inducement Awards
January 30, 2020 16:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities
January 09, 2020 07:30 ET
|
Strongbridge Biopharma plc
~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018...
Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director
November 18, 2019 07:30 ET
|
Strongbridge Biopharma plc
~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of...
Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences
November 12, 2019 07:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 07, 2019 07:30 ET
|
Strongbridge Biopharma plc
~ KEVEYIS® (dichlorphenamide) Achieved $5.7 Million in Revenue Along with a Positive Contribution Margin in Third Quarter of 2019; Strongbridge Remains On-Track to Meet or Exceed the Top End of...